Rare & Orphan Lab · DeCure for X
DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for spondyloepiphyseal dysplasia, Kimberley type — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
No approved-drug candidate for spondyloepiphyseal dysplasia, kimberley type is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
aggrecan (ACAN) — ACAN is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
RCSB Protein Data Bank · entry 9DFF · 2.59 Å · ligand beta-D-glucopyranuronic acid (BDP). Experimental structure, not a prediction.
An adult female with a sporadic form of spondyloepiphyseal dysplasia tarda showed universal platyspondyly, short metacarpals and metatarsals, genu valgum, mild thoracic kyphoscoliosis, and severe generalised epiphyseal distortion with premature osteoarthrosis. Seven cases of spondyloepiphyseal dysplasia tarda presented uniformly with shortening of stature and pains in the spine and large joints secondary to early osteoarthritic changes; hump-shaped lower thoracic and lumbar vertebral bodies were the diagnostic feature.
The eighth reported case of spondyloepiphyseal dysplasia, Kondo-Fu type (SEDKF), a 20-year-old male, presented with severe disproportionate short stature and spondyloepiphyseal dysplasia plus the previously unreported feature of cutis laxa. Whole exome sequencing identified compound heterozygosity for a predicted splicing variant and a complete gene deletion in the MBTPS1 gene. RNA splicing assays confirmed aberrant splicing, establishing the molecular diagnosis. Only seven SEDKF cases had been reported in the literature before this one.
No drug treatment was tested or proposed in any of these reports. The abstracts contain no data on survival, response rates, or sample sizes for any intervention. The natural history described is uniform: early osteoarthritic pain and progressive skeletal deformity, with no therapy mentioned.
What is still missing is any clinical trial, any drug repurposing hypothesis, any patient stratification strategy, and any funding for treatment research in these ultra-rare conditions. The molecular basis of SEDKF (MBTPS1) has only recently been identified, and no functional studies linking it to a druggable pathway have been reported in these abstracts.
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
AbstractWe report a sporadic adult female with a distinctive variety of spondyloepiphyseal dysplasia tarda characterised by universal platyspondyly, short metacarpals, short metatarsals, genu valgum, mild thoracic kyphoscoliosis, and severe generalised epiphyseal distortion with premature osteoarthrosis.
https://doi.org/10.1136/jmg.19.3.234AbstractSUMMARY Seven cases of spondyloepiphyseal dysplasia tarda are reported. The disease has a very uniform clinical presentation ‐ shortening of stature with pains in spine and large joints secondary to early osteoarthritic changes ‐ with little variability. hump &aped lower thoracic and lumbar vertebral bodies are the diagnostic feature Of the disease.
https://doi.org/10.1111/j.1440-1673.1983.tb02452.xAbstractSpondyloepiphyseal dysplasia, Kondo-Fu (SEDKF) type is a rare skeletal dysplasia caused by biallelic variants in MBTPS1. To date, only seven SEDKF cases have been reported in the literature. Here, we report the eighth, a 20-year-old male presenting with severe disproportionate short stature, spondyloepiphyseal dysplasia, and the previously unreported feature of cutis laxa, which led to the clinical suspicion of geroderma osteodysplasica. Whole exome sequencing identified compound heterozygosity for a predicted splicing variant and a complete gene deletion in the patient. Functional validation using RNA splicing assays confirmed aberrant splicing, establishing the molecular diagnosis of SEDKF. This case broadens the clinical and molecular spectrum of MBTPS1-related disorders by presenting a novel combination of variants and phenotypic features.
https://doi.org/10.1111/cge.70084Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
